Company: Sun Pharmaceutical Industries Ltd.


The Nifty Pharma index soared 1.7% led by Sun Pharma, Dr Reddys, Cipla and Lupin.
Aug. 19, 2019, 9:29 a.m.

In June 2019, Sun Pharma had announced collaboration with CMS on two speciality products, Tildrakizumab and Cyclosporine A 0.09% (CsA) eye drops for the Greater China market.
Aug. 19, 2019, 9 a.m.

In June 2019, Sun Pharma had announced collaboration with CMS on two speciality products, Tildrakizumab and Cyclosporine A 0.09% (CsA) eye drops for the Greater China market.
Aug. 19, 2019, 9 a.m.

Check out the companies which will be in focus during trade today based on recent and latest news developments.
Aug. 19, 2019, 8:04 a.m.


The total addressable market size for all these eight products is about $1 billion (according to recent IQVIA data) in mainland China
Aug. 16, 2019, 8:48 p.m.

To pay upfront fee of Rs 240 crore for potential development, regulatory and sales milestone
Aug. 14, 2019, 4:11 p.m.

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications
Aug. 14, 2019, 1:50 p.m.

Markets fear sustainability of performance; stock down over 5%
Aug. 14, 2019, 1:29 p.m.

Under the terms of the license agreement, Sun Pharma gets exclusive global license for the said patents and any other future patents covered in the agreement.
Aug. 14, 2019, 12:55 p.m.

India's largest drugmaker has raised focus on specialty and limited competition products in the wake of pricing pressure in the US
Aug. 13, 2019, 10:01 p.m.

-->